Le Lézard
Classified in: Health, Science and technology

FluoGuide A/S Publishes Interim Report for the Period January - September 2023

KØBENHAVN, DENMARK / ACCESSWIRE / November 29, 2023 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 29 November 2023 - FluoGuide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January - 30 September 2023. The Q3 report is available as an attached document to this press release and on FluoGuide's website.

In Q3 2023, FluoGuide completed patient recruitment for two clinical phase II trials of FG001, in aggressive brain cancer and head and neck cancers. The positive results in these indications, some of which were published after the end of Q3, as well as positive phase II data in lung cancer reported earlier in 2023, put FluoGuide in a uniquely promising position. Financial flexibility enables the Company to fully capitalize on the good clinical results.

FluoGuide had no revenue for the period and posted a net result of TDKK -9,314 (TDKK -7,041) for the period 1 January to 30 September 2023. The financial result for the period is in line with the Company's development plans.

SummaryQ3 23Q3 22YTD 2023YTD 20222022
DKK thousands1-Jul-231-Jul-221-Jan-231-Jan-221-Jan-22
Net Revenue-----
Operating result-10,862-8,416-31,164-21,358-32,461
Net result-9,314-7,041-25,990-16,743-27,340
Cash and bank8,94531,7008,94531,70026,013
Result per share (DKK) *)-0.78-0.60-2.19-1.43-2.33
Solidity (%) **)73%91%73%91%90%

*) Result per share (DKK per share): Operating result divided by the average number of shares during the period.
**) Solidity: Total equity divided by total capital and liability.



For further information, please contact:
Morten Albrechtsen, CEO,
FluoGuide A/S
+45 24 25 62 66,
[email protected]

About FluoGuide

FluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company's lead product, FG001, is designed to improve surgical precision by illuminating cancer intraoperatively. This improved precision enabled by FluoGuide's products is expected to have a dual benefit - it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient's chance of achieving a complete cure and will lower system-wide healthcare costs.

The Company has published key results on the efficacy of FG001 as well as showing it was well tolerated and safe from clinical trials in patients with aggressive brain cancer (high-grade glioma) that undergo surgery. In addition, FluoGuide has demonstrated the effect of FG001 in lung and head & neck cancers.

For more information on the Company, please visit www.fluoguide.com

FluoGuide Q3 2023

SOURCE: FluoGuide A/S

View source version on accesswire.com:

These press releases may also interest you

at 03:43
During 26 February 2024 and 1 March 2024 Truecaller AB (publ) (LEI code 549300TEYF1FA5G5GK26) has repurchased in total 458,868 own B shares (ISIN: SE0016787071) as part of the share buyback programme initiated by the board of directors. The share...

at 03:39
Hikvision unveiled a captivating array of innovative display technologies and products at Integrated Systems Europe (ISE) 2024 in Barcelona, Spain. Integrated Systems Europe (ISE), which takes place every February, is the largest audio-video systems...

at 03:36
The European Society of Gynecological Oncology (ESGO) 2024 Conference has recently made selected abstracts available online. The abstract (abstract # 251) that details results from the Phase II clinical trial (DUBHE-C-206) evaluating the efficacy and...

at 03:30
Samyang Group announced that KCI (CEO Jinyong Lee), a subsidiary specializing in cosmetics and personal care materials, won 'Platinum Medal', the highest grade, in the 2024 Sustainability Rating from 'EcoVadis', a global ESG rating agency....

at 03:28
OKX, a leading Web3 technology company, has issued updates for March 4, 2024. OKX Launches Snap Quest Campaign with 5,000 USDT Reward...

at 03:15
Vanair, the leading manufacturer of Mobile Power Solutions, has announced the introduction of three versatile adapter kits for its dual voltage Start?All Jump?Pack12/24V lithium-ion jump-starter by Goodall. Each kit comes complete with all the...

News published on and distributed by: